Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Vicore Pharma Holding ABNASDAQ: VCRE

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables dips below year-ago levels

Q2 FY2026 accounts receivables of SEK 232.06K (cash outflow) fell 95.0% year over year, behind the +561.8% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Accounts receivables amounted to 80.7% of revenue in FY2025, up 48.1 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -95.0% toward the trailing-twelve-month pace of +561.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-SEK 232.06K-102.1% QoQ
Last fiscal yearDec 2025
-SEK 3.08M-91.4% YoY
LTMJun 2026
-SEK 8.69M+561.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-95.0%——
1 year-91.4%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

SEK · from the cash flow

Latest · FY2025
(3.08M) SEK
Year-over-year change
+91.4%

Accounts Receivables vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +561.8% is the lowest of 2, against a peer median of +1833.7%.
  • Accounts receivables amounts to 653.7% of revenue for VCRE, versus a peer median of 28.8%.
VCRE Competitors
Accounts Receivables for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$129.93M USD+1833.7%+193.7%28.8%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 8.69M SEK+561.8%+24.4%653.7%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+1833.7%+193.7%28.8%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.